The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4-1BB enhance the proliferation and survival of antigen-stimulated T cells in vitro and promote CD8 T cell-dependent anti-tumor immunity in pre-clinical cancer models. We found that T regulatory (Treg) cells infiltrating human or murine tumors expressed high amounts of 4-1BB. Intra-tumoral Treg cells were preferentially depleted by anti-4-1BB mAbs in vivo. Anti-4-1BB mAbs also promoted effector T cell agonism to promote tumor rejection. These distinct mechanisms were competitive and dependent on antibody isotype and FcgR availability. Administration of anti-4-1BB IgG2a, which preferentially depletes Treg cells, followed by either agonistic anti-4-1BB IgG1 or anti-PD-1 mAb augmented anti-tumor responses in multiple solid tumor models. An antibody engineered to optimize both FcgR-dependent Treg cell depleting capacity and FcgR-independent agonism delivered enhanced anti-tumor therapy. These insights into the effector mechanisms of anti-4-1BB mAbs lay the groundwork for translation into the clinic.
In Brief
Buchan et al. reveal dual anti-tumor activities for antibodies to the costimulatory receptor 4-1BB, which depend on antibody isotype and FcgR availability. Sequential scheduling of anti-4-1BB and checkpoint blockade mAbs, and antibodies engineered to harness both Treg cell depleting and effector cell agonism properties show potent antitumor activity in preclinical models, laying the groundwork for translation into the clinic.
INTRODUCTION
Immunomodulatory monoclonal antibodies (mAbs), such as anti-CTLA-4, anti-PD-1/PD-L1, and anti-CD40, show positive outcomes when trialed in difficult-to-treat malignancies, albeit in a minority of patients (Beatty et al., 2011; Brahmer et al., 2012; Hodi et al., 2010; Topalian et al., 2012) . These promising results reinforce the belief that the immune system holds the key to controlling cancer. Immunomodulatory mAbs are directed at key molecular regulators on T cells or antigen-presenting cells (APCs) and boost anti-cancer immunity through blockade of inhibitory signals (checkpoint blockers) or delivery of co-stimulatory signals (agonists). Recently, this binary classification has been called into question by data showing that the therapeutic activities of T cell-targeting mAbs anti-CTLA-4, anti-GITR, and anti-OX40 involve depletion of suppressive CD4 + T regulatory (Treg) cells dependent on co-engagement of activatory FcgRs (Bulliard et al., 2013; Marabelle et al., 2013; Simpson et al., 2013) . The activity of agonistic APC-targeting anti-CD40 mAbs, in contrast, requires co-engagement of the inhibitory FcgR to facilitate effective mAb cross-linking, which is necessary for CD40 signaling and immune stimulation (Li and Ravetch, 2011; . Therefore, the mechanisms employed by immunomodulatory mAbs depend on their Fab and Fc regions in ways that are ill defined and which may depend on the cell type being targeted. Understanding the relative importance of Treg cell depletion versus direct immune stimulation will be vital to the development and successful translation of immunomodulatory mAbs to patients. Like CD40, 4-1BB is a member of the TNFR superfamily and a promising target for cancer immunotherapy. 4-1BB is expressed following activation of CD4 + and CD8 + T cells and its ligation is required for optimal protective CD8 T cell responses against viruses and B cell lymphoma in mice (Middendorp et al., 2009; Snell et al., 2011) . Anti-4-1BB mAbs enhance the proliferation and survival of antigen-stimulated T cells in vitro and, similar to anti-CD40, promote anti-tumor immunity in pre-clinical cancer models, dependent largely on CD8 T cells (Melero et al., 2013; Snell et al., 2011) . Given the agonistic nature of anti-4-1BB and the structural similarities between 4-1BB and CD40, it might be anticipated that anti-4-1BB mAbs operate through a similar mechanism to anti-CD40 mAbs. However, unlike CD40, 4-1BB is a downstream target of the Treg cell lineage-defining transcription factor Foxp3; it is expressed on resting Treg cells and is increased on Treg cell activation (Marson et al., 2007; McHugh et al., 2002) . It is possible therefore that anti-4-1BB may act in part through the depletion of Treg cells.
Whether anti-4-1BB is a depleting or a stimulating antibody is likely to depend on its FcgR engagement and we have therefore explored the optimal isotype for therapeutic anti-4-1BB mAbs in tumors. We found that although a mIgG1 isotype mAb exerted superior agonistic activity and direct immune stimulation of CD8 + T cells, in established solid tumor settings, the mIgG2a mAb provided optimal therapeutic activity due to intratumoral Treg cell depletion. However, when depletion was prevented, in mice lacking activatory FcgR, the therapeutic potential of the mIgG2a was retained. Under these conditions mIgG2a was converted to an agonist by preferential engagement of the inhibitory FcgR, FcgRIIB. We further established that depletion and agonism are competing mechanisms and that engaging both simultaneously led to reduced efficacy. This blunting of activity could be overcome through sequential administration of Treg cell depleting and then immunostimulatory isotypes or through IgG-hinge engineering to produce a dual-activity anti-4-1BB mAb possessing optimal FcgR-depleting capacity together with FcgR-independent agonism. These results have implications for the administration of existing and in-development immunomodulatory mAbs and for the design of next generation reagents.
RESULTS
The Therapeutic Activity of Anti-4-1BB mAbs Is Determined by Isotype We and others have previously established the dependence of immunostimulatory TNFR superfamily-targeting mAbs on cross-linking provided by the inhibitory FcgRIIB (Li and Ravetch, 2011; . To establish whether this requirement similarly applies to anti-4-1BB in a solid tumor setting, we generated mIgG1 and mIgG2a chimeric versions of the rIgG2a anti-4-1BB mAb (LOB12.0 generated in-house [Beers et al., 2008; Taraban et al., 2002; White et al., , 2014b ). Analysis by surface plasmon resonance and flow cytometry established that these mAbs possessed an expected mFcgR-binding profile, with mIgG2a having a high activatory to inhibitory FcgR-binding ratio (A:I) and conversely mIgG1 a low A:I ( Figure S1A ; Nimmerjahn and Ravetch, 2005; White et al., 2014b) ; both mAbs retained equivalent 4-1BB specificity and binding (Figures S1B and S1C) . We then assessed the therapeutic potential of these mouse anti-4-1BB mAbs in three different established solid tumor models: CT26 colon carcinoma ( Figure 1A ), EG7 thymoma ( Figure 1B) , and NXS2 neuroblastoma ( Figure 1C ). In contrast to our studies with anti-CD40 (White et al., , 2014b and published reports with other agonistic anti-TNFR superfamily mAbs targeting DR5 (Haynes et al., 2010; Li and Ravetch, 2012a) , the high A:I mIgG2a mAb gave considerable therapeutic benefit (80% long-term survival in all three models) while the low A:I mIgG1 version delayed growth of CT26 and EG7 but failed to confer significant long-term benefit (0%-20% survival). The therapeutic efficacy of mIgG2a mAbs was dependent upon CD8 + T cells (Figure S2A ) and led to long-term protective anti-tumor immunity, as determined by tumor re-challenge experiments ( Figure S2B ). These results show that the protective effect of mIgG2a anti-4-1BB is mediated through an adaptive anti-tumoral immune response.
4-1BB Is Expressed on Intratumoral Treg Cells in Mice and Humans
Having established that anti-4-1BB mIgG2a was more therapeutic than mIgG1 in treating wild-type mice with established tumors, we looked for mechanisms that could explain the immunomodulatory activity of anti-4-1BB mIgG2a. 4-1BB mRNA and protein are preferentially expressed in Treg cells compared to resting effector T cells (Elpek et al., 2007; Gavin et al., 2002; McHugh et al., 2002) and 4-1BB protein is further increased following Treg cell activation (Elpek et al., 2007; Zheng et al., 2004) . Furthermore, 4-1BB is increased, at least at the transcriptional level, in intratumoral Treg cells in human solid cancers (De Simone et al., 2016; Plitas et al., 2016) . We therefore examined the possibility that anti-4-1BB mIgG2a could potentiate an antitumor response via depletion of Treg cells. We began by confirming that 4-1BB was expressed on a substantial proportion of tumor-infiltrating Treg cells and only a small minority of effector T cells in CT26, EG7 (Figure 2A ), and NXS2 (data not shown) and found that furthermore, only a small fraction of splenic Treg cells expressed 4-1BB. To confirm that these observations are potentially translatable to humans, we determined by flow cytometry whether 4-1BB was present on intratumoral Treg cells in patients with ovarian cancer ( Figure 2B ) and squamous cell carcinoma ( Figure 2C ). In both cases 4-1BB was primarily on Treg cells with lower and variable expression on effector CD4 + or CD8 + T cells in tumors (Figures 2B and 2C) . Furthermore, 4-1BB was expressed at lower levels on Treg cells isolated from healthy PBMCs, matched blood, ascites, or normal skin.
4-1BB Expression on Intratumoral Treg Cells Is Required for mIgG2a Therapy and Its Depletion Potential Is Determined by Expression Level
Having determined that intratumoral Treg cells express 4-1BB, we used the CT26 and EG7 tumor models to investigate the depleting capacity of anti-4-1BB mAb. In wild-type CT26 tumor-bearing mice, the mIgG2a mAb efficiently depleted intratumoral Treg cells, while the mIgG1 variant was ineffective (Figure 3A, left) . This depletion effect was restricted to the tumor and dependent upon expression of the Fc receptor g chain, a crucial component of activatory FcgR complexes ( Figure 3A , left and right). In mice lacking expression of FcgRIIB, the depleting activity of the mIgG1 mAb was significantly enhanced, demonstrating that the depletion efficiency of these mAbs is intimately linked to FcgR availability and that depletion potency can be manipulated through changes in FcgR expression. Next, we sought to demonstrate definitively that 4-1BB-dependent Treg cell depletion was the main mechanism of therapeutic action of the mIgG2a isotype in solid tumors. In order to do this, we generated mice expressing floxed Tnfrsf9 on a C57BL/6 background and crossed these with mice in which Foxp3 was flanked by sequence encoding Cre recombinase (Rubtsov et al., 2008) to generate mice in which Treg cells exhibit specific genetic deletion of Tnfrsf9 ( Figures S3A-S3D ). We first confirmed that mice with a Treg cell-specific ablation of the Tnfrsf9 allele (Tnfrsf9 Foxp3À/À ) lack 4-1BB expression on Treg cells but maintain levels on activated CD8 T cells in the tumor ( Figure S3C ). EG7 tumors were established in these mice and Treg cell depletion in the tumor microenvironment monitored. As seen in the CT26 model, mIgG2a, and not mIgG1, efficiently depleted intratumoral Treg cells in the floxed control mice but this activity was lost in mice lacking 4-1BB expression on Treg cells ( Figure 3B ). Furthermore, in keeping with our contention that Treg cell depletion is the primary mechanism of action of anti-4-1BB mIgG2a, the long-term therapeutic benefit of mIgG2a was lost in mice lacking 4-1BB on Treg cells ( Figure 3C ). Although when characterizing the Tnfrsf9 Foxp3À/À strain we observed comparable frequencies of Treg cells throughout the lymphoid compartment compared to WT and Tnfrsf9 fl/fl controls (data not shown), the intratumoral Treg cell frequencies were reduced, implying a possible role for 4-1BB in supporting intratumoral Treg cell numbers. We next sought to formally demonstrate the depleting capacity of anti-4-1BB mAbs. Using WT mouse bone-marrow-derived macrophages and 4-1BB-expressing T cell targets, we observed that mIgG2a induced effective phagocytosis of target cells whereas the mIgG1 mAb was ineffective ( Figure 3D ). In agreement with our in vivo depletion results ( Figure 3A) , when Fcgr2b À/À macrophages were used as effectors, a significant increase in mIgG1-mediated phagocytosis was observed (Figure 3D) in line with levels obtained with mIgG2a and WT effectors. To confirm the translational potential of our findings, we additionally used human target cells and monocyte-derived macrophage effectors. In this system we found that two different anti-human 4-1BB clones (SAP3-6 and 005-B02; both of hIgG1 isotype and with A:I FcgR-binding ratios comparable to anti-4-1BB mIgG2a) (Vonderheide and Glennie, 2013) could mediate effective phagocytic clearance (Figure 3E, left) . We then sought to confirm that the level of 4-1BB expression rather than the cell type per se dictated the efficacy of depletion. We did this using both human ( Figure 3E , right) and mouse (data not shown) in vitro generated macrophages and target cells with varying levels of 4-1BB expression and found a direct correlation between the level of 4-1BB expression on target cells and the efficiency of target cell depletion. Finally, we tested the depletion efficiency of anti-4-1BB mAbs on human T cell targets in vivo. Human PBMCs transferred to the peritoneal cavity of immunocompromised mice became activated and expressed 4-1BB. In this setting CD127 lo CD25 hi Treg cells expressed significantly higher levels of 4-1BB than CD8 + T cells ( Figure 3F ), mirroring levels seen in human tumors (Figures 2B and 2C) . When human IgG1 anti-human 4-1BB mAbs were administered to these mice, significant and preferential depletion of Treg cells versus CD8 + T cells was observed ( Figure 3G ). Taken together, these data support the contention that the high level of 4-1BB expressed on Treg cells in the tumor microenvironment makes them more susceptible to 4-1BB-dependent depletion compared with lower expressing CD8 + cells. CT26 and EG7, respectively), suggesting that Treg cell depletion may not fully account for its therapeutic activity. In contrast to the minimal effects on anti-4-1BB mIgG2a efficacy, there was a substantial improvement in the ability of anti-4-1BB mIgG1 to promote anti-tumor immunity in the absence of activatory FcgR in both models. These findings suggest that in the absence of competitive binding of mAbs to activatory FcgR, both mIgG1 and mIgG2a engage FcgRIIB efficiently, likely allowing optimal cross-linking of mAbs to deliver costimulation. In keeping with the enhanced Treg cell-depleting activity of mIgG1 in Fcgr2b À/À mice ( Figure 3A) , the mIgG1 isotype mAb demonstrated equivalent activity to mIgG2a in Fcgr2b À/À mice ( Figure 4A ). These results, coupled with the observation that in the absence of all FcgR (Fcer1g
), neither mAb produced any therapeutic activity ( Figure 4A ), underscore the importance of efficient, non-competing FcgR engagement for optimal in vivo activity. Data points represent individual patients/ donors with n = 11 for healthy PBMCs, n = 20 for ascites, n = 9 for tumor, and n = 5 for patient blood (whiskers = min to max).
(C) Samples of freshly excised cutaneous squamous cell carcinoma (SCC), normal skin, and matched blood were obtained from patients at surgery. Samples were minced and digested before separation with a density gradient. Peripheral blood mononuclear cells were separated by centrifugation. Cells were stained for 4-1BB and staining detected by flow cytometry. Top panels show representative histograms with 4-1BB staining shown as open histograms; tumor tissue (blue), blood (green), normal skin (red), and isotype control (gray). Lower panel shows 4-1BB expression on T cell subsets from different tissue samples. Data points represent individual patients/donors with n = 7 for normal skin, n = 10 for tumor, and n = 9 for matched patient blood (whiskers = min to max).
CD8 T Cell Immunostimulatory Activity of Anti-4-1BB Is Optimal as a Mouse IgG1 Isotype
We next sought to establish the isotype dependence of anti-4-1BB mAb agonist activity in vitro and in vivo. Using in vitro T cell co-stimulation assays ( Figures 5A and S4 ), mIgG1 demonstrated superior agonistic activity compared with mIgG2a, in keeping with published results using other TNFR superfamily targeting mAbs (White et al., 2011, 2014b) . The costimulatory activity observed for mIgG1 was independent of Treg cells ( Figure 5A ), suggesting that this anti-4-1BB mAb mediates its effects through targeting 4-1BB on effector T cells. Further, the costimulatory activity of mIgG1 was abolished by the addition of mIgG2a (Figure 5B) , confirming that both mAb variants bind with similar avidity and compete for binding to 4-1BB on effector T cells (Figures 5B and S1B) . These in vitro results were confirmed using an in vivo immunization model with the model antigen OVA in both an endogenous ( Figure 5C ; left) and an OT-1 T cell transfer (Figure S5A) setting. In this context the superior agonistic activity of (G) Splenic cells isolated from NOG mice were transferred i.p. into SCID mice. 1 hr later, mice were treated i.p. with anti-4-1BB hIgG1, with control mAbs, or with 10 mg/kg alemtuzumab as a positive control for depletion. Intraperitoneal fluid was collected after 24 hr and frequency of human T cell subsets was determined by flow cytometry. See also Figure S3 . mIgG1 was dependent upon the inhibitory FcgRIIB (Figures 5C, right and S5A) as previously shown for anti-CD40 mAbs (Mimoto et al., 2013; White et al., 2015 White et al., , 2014b . Similarly, and in support of the in vivo therapy observed by mIgG2a mAbs in Fcer1g À/À mice ( Figures 4A and 4B ), agonistic activity of mIgG2a was revealed in treated Fcer1g À/À animals ( Figure 5C , right).
These data demonstrate that mechanisms with differential FcgR requirements effectively compete with each other and the therapeutic outcome of mAb treatment is dependent on mAb Fc binding profiles and FcgR availability. Having established that mIgG1 was the optimal isotype for agonistic activity, we wanted to establish whether this agonistic activity was mediated through direct immune activation of 4-1BB-expressing CD8 + T cells. In order to do this, we generated a full Tnfrsf9
À/À mouse model on a C57BL/6 background (Figure S3A) and transferred in purified OT-1 CD8 + T cells which were WT for Tnfrsf9 and therefore express 4-1BB under normal physiological regulation. These mice were then challenged with OVA and anti-4-1BB mAbs. In keeping with the results in WT 4-1BB-expressing mice ( Figures 5C and S5A ), we observed that anti-4-1BB mIgG1 produced a robust tetramer positive CD8 + T cell response when 4-1BB expression was restricted to CD8 + T cells ( Figure 5D ), supporting our contention that 4-1BB costimulatory activity is induced through direct activation of CD8 + T cells.
We next sought to determine whether we could observe activation of tumor-infiltrating CD8 + T cells in mIgG1-and mIgG2a-treated CT26 and EG7 tumor-bearing mice. Administration of mIgG1 or mIgG2a mAbs to tumor-bearing mice led to an increase in tumor-infiltrating CD8 + T cells expressing Ki-67 and KLRG1 in the CT26 and EG7 tumor models, respectively (Figures 5E and 5F), although the increase induced by the mIgG2a isotype was significantly less than that driven by mIgG1. Notably, mIgG1-dependent CD8 T cell agonistic effects were not affected by the loss of 4-1BB on Treg cells ( Figure 5F ), supporting the notion that this activity is mediated through direct activation of the CD8 + T cells.
Finally, we used two vaccination strategies (tyrosine hydroxylase peptide with the NXS2 tumor and irradiated B16/BL6 cells engineered to secrete a form of Flt3L [FVAX] ; Figures 5G, right and S5B, respectively) to increase the therapeutic effect of mIgG1 and found that in these immune-primed settings, both mIgG1 and mIgG2a isotype mAbs were equally therapeutic. Of note, the efficacy of mIgG1, but not mIgG2a, was abolished in the absence of vaccination ( Figure 5G, left) . Taken together, these data confirm that mIgG1, but not mIgG2a, operates primarily through a mechanism dependent on FcgRIIB cross-linking and direct immune activation of CD8 + T cells.
Sequential Administration of Treg Cell Depleting and Immunostimulatory mAbs Leads to Enhanced Anticancer Therapy
Our results demonstrating that the therapeutic activities of isotype variants of anti-4-1BB mAbs occur via different mechanisms indicated a potential for combined use to enhance therapy. However, since depletion of Treg cells (mIgG2a) and delivery of costimulation (mIgG1) both relied on engagement of FcgRs, and appeared to do so in a competitive manner, we speculated that sequential rather than concurrent administration might be optimal. We therefore compared the therapeutic effect of concurrent and sequential administration of anti-4-1BB mIgG2a and mIgG1 mAbs. As previously observed, the mIgG2a, but not mIgG1, variant was active as a single agent ( Figure 6A ). Concurrent administration of mIgG2a and mIgG1 anti-4-1BB mAbs resulted in reduced therapeutic efficacy as indicated by increased tumor size ( Figure 6A ) and reduced frequency of tumor-free mice ( Figure 6B ) compared to mIgG2a single-agent treatment. In contrast, sequential delivery of first mIgG2a, to deplete Treg cells, followed 4 days later by agonistic mIgG1 to provide costimulation improved both tumor control and the frequency of tumor-free mice ( Figures 6A and 6B ). These findings demonstrate that the therapeutic efficacy of FcgR-dependent immunomodulatory mAbs can be optimized by sequential administration and indicate that 4-1BB-mediated Treg cell depletion may have broad utility to improve the efficacy of other immune-modulatory antibodies, including checkpoint blockers. We therefore investigated the therapeutic potential of combining Treg cell-depleting anti-4-1BB with an antibody targeting the PD-1 checkpoint receptor. We reduced the dosing of mIgG2a mAbs to obtain suboptimal monotherapy and then combined anti-4-1BB mIgG2a sequentially with a deglycosylated variant anti-PD-1 blocking antibody, incapable of binding FcgRs (Tipton et al., 2015) (Figures S6A and S6B ) and which therefore mimics the poor FcgR engagement of clinically validated anti-PD-1 antibodies nivolumab and pembrolizumab (Dahan et al., 2015) . This combination produced a significant increase in therapy leading to 80% long-term responders compared with 20%-25% with either monotherapy ( Figure 6C ). The combination of anti-4-1BB mIgG1 and wild-type anti-PD-1 did not enhance responses compared with either monotherapy, demonstrating that for optimal combination therapies, it is vital to understand the impact of isotype and scheduling of each component of any combination.
Anti-4-1BB mIgG2a/h2B Engineered to Possess Dual Activity Delivers Augmented Cancer Therapy We next investigated whether it is possible to effect both agonism and depletion through the engineering of a single mAb. Given that mAb-mediated Treg cell depletion and immunostimulatory agonism have differential and competing FcgR requirements, we sought to capitalize on our previous finding that the human IgG2 hinge region is able to impart anti-TNFR superfamily member mAb with FcgR-independent agonistic properties (White et al., 2015) . Here, we cloned the human IgG2 CH1 and hinge region into the murine mIgG2a constant regions of anti-4-1BB as detailed previously (White et al., 2015) and then skewed the hinge to the agonism-enhanced ''B'' form to make anti-4-1BB mIgG2a/h2B ( Figures S7A and 7A ). When tested in vitro, mIgG2a/h2B had significantly enhanced agonistic activity compared to the mIgG2a parental mAb ( Figure 7B ), despite an unchanged FcgR binding profile ( Figure S7B ). Despite this enhanced agonistic activity, the engineered mAb also retained strong phagocytic potential in vitro ( Figure 7C ). Finally, we compared this mAb with the parental mIgG2a in vivo and found that the dual activity mIgG2a/h2B had equally potent Treg celldepleting capacity as the parental mIgG2a but now also possessed marked CD8 T cell-stimulating capability leading to an enhanced intratumoral CD8/Treg cell ratio ( Figure 7D ). This dual-activity mAb also demonstrated greater therapeutic potential, curing 86% of mice compared to 53% with the standard mIgG2a ( Figure 7E ). These data demonstrate that a single mAb can be engineered to optimally mediate depletion and agonism, and through this enhanced dual activity deliver better therapy.
DISCUSSION
It has been established in a variety of in vitro and in vivo models that anti-TNFR superfamily mAbs require efficient cross-linking to induce their agonistic effects and for most mAbs this is best achieved by inhibitory FcgR engagement (Li and Ravetch, 2011 , 2012a , 2012b White et al., , 2014b . Despite these findings, it is not clear whether direct agonism is the main mechanism of therapeutic activity of these mAbs in a solid tumor setting. We have investigated this question using mIgG2a and mIgG1 isotype anti-4-1BB mAbs, which have a high and low activatory:inhibitory FcgR-binding ratio, and consequently good depleting and agonistic potential, respectively (White et al., 2014a).
We found using three different solid tumor models in different wild-type strains of mice that mIgG2a mAbs produced substantial therapeutic effects whereas mIgG1 was less effective. The mIgG2a-dependent therapeutic activity displayed in these different tumor models suggested that therapy was likely mediated by an effector cell-dependent depletion mechanism. None of the tumors used were 4-1BB positive (data not shown), meaning this could not be a direct tumor-targeting effect as seen for anti-CD20 mAbs (Minard-Colin et al., 2008) .
Given the recent findings that mAbs targeting CTLA-4, OX40, and GITR are able to mediate therapy through intratumoral Treg cell depletion (Bulliard et al., 2013; Marabelle et al., 2013; Simpson et al., 2013) , we examined 4-1BB expression in these models and found it to be highly expressed on intratumoral Treg cells. Importantly for the potential translation of these findings to humans, we found that 4-1BB demonstrated restricted expression on intratumoral Treg cells in patients with both ovarian cancer and squamous cell carcinoma, supporting the therapeutic potential of this approach in patients. Furthermore, mIgG2a depleted this suppressive population in an activatory FcgR-dependent manner, while mIgG1 had little effect. In keeping with the requirement for a high activatory to inhibitory FcgR-binding ratio for productive depletion, when these experiments were carried out in Fcgr2b À/À mice, mIgG1 exhibited comparable depleting capacity to mIgG2a both in vivo and in vitro. Treg cell depletion was as a result of direct targeting as mice deficient for 4-1BB on Treg cells were resistant to depletion and the mIgG2a therapeutic effect was diminished in these mice. Treg cell-specific depletion appeared to simply result from higher 4-1BB expression on Treg cells as compared to CD8 + T cells rather than cell-specific susceptibility or resistance and led to selective depletion of mouse and human Treg cells in vivo.
Although Treg cell depletion was the most effective mechanism of action for 4-1BB mAbs in these models, we postulated that in the absence of competition for binding with activatory FcgR, these mAbs may produce a therapeutic effect through their agonistic function. We tested this using the CT26 and EG7 models in Fcer1g À/À mice and found that in the absence of activatory FcgR, mIgG1 mAbs did become therapeutic. It was also notable, and in keeping with our contention that 4-1BB has a relatively low threshold for cross-linking in vivo, that in the absence of activatory FcgR, mIgG2a also retained activity. In agreement with the enhanced Treg cell-depleting activity of mIgG1 in Fcgr2b À/À mice, when therapies were carried out in Fcgr2b À/À mice bearing CT26 tumors the mIgG1 isotype mAb demonstrated enhanced and equivalent activity to mIgG2a. Neither mAb was able to protect mice in the complete absence of FcgR demonstrating both agonistic and depletion mechanisms to be FcgR dependent. The depletion-dependent effects discussed above were in marked contrast to the agonistic activity of these mAbs on CD8 + T cells, where mIgG1 was more effective. In contrast to previous publications with anti-CD40 mAbs, anti-4-1BB mIgG2a was not without direct T cell agonistic activity in vitro and in vivo, suggesting that 4-1BB may possess a lower crosslinking threshold for signaling than CD40 (White et al., , 2014b . The fact that anti-4-1BB mAbs could be therapeutic using two separate mechanisms, given the provision of the appropriate FcgR, suggests that both mechanisms could be engaged if mAbs were administered sequentially. Indeed, this was found to be the case when mIgG2a was given first to deplete Treg cells and then mIgG1 given to deliver an agonistic signal; when mAbs were administered simultaneously, then little therapeutic effect was evident. These observations support the hypothesis that simultaneous engagement of these two FcgR-dependent mechanisms through the engagement of a single antigen may not be possible but that temporal, as shown here, or potentially spatial (intratumor versus systemic) separation of these mAbs may facilitate their combined efficacy.
In order to further demonstrate the likely isotype and scheduling requirements for anti-4-1BB mAbs in patients, where clinical results suggest combination approaches are likely to be required, we investigated different mAb combinations with anti-PD-1. In this setting we found that isotype-optimal versions of both anti-4-1BB and anti-PD-1 produced a significant combination effect, leading to cures in 80% of mice treated.
In the clinic there has been much interest in targeting 4-1BB using agonistic antibodies. Our finding that 4-1BB expression was more abundant on intratumoral Treg cells than CD8 T cells and that anti-4-1BB mAbs specifically deleted Treg cells in animal models suggests that this strategy may be particularly appealing in patients. In support of the potential of this approach, two small clinical studies have reported a correlation between Treg cell depletion in tumors and therapeutic response to anti-CTLA-4 mAb therapy (Romano et al., 2015; Arce Vargas et al., 2018) .
Currently two fully humanized anti-4-1BB mAbs are in development: urelumab (BMS-663513), an IgG4 antibody manufactured by Bristol-Myers Squibb, and utomilumab (PF-05082566), a fully humanized IgG2 produced by Pfizer. Thus far, utomilumab has proven safe, causing only grade 1 toxicities in patients (Segal et al., 2014), whereas urelumab caused adverse effects in 15% of patients including increased liver enzymes, pruritus, and diarrhea (Molckovsky and Siu, 2008) . Despite their promising safety profiles, neither urelumab or utomilumab are predicted to strongly bind FcgRIIB or deplete Treg cells calling into question whether either antibody will prove effective in patients (Furness et al., 2014) . Data from our group show that a human IgG2 antibody targeting 4-1BB can act as a superagonist independent of FcgR and it remains possible that utomilumab might act in a similar manner (White et al., 2015) . Alternatively, the data presented herein demonstrating improved efficacy of Treg cell depleting compared with immune-agonist variant anti-4-1BB antibodies, and selective intratumoral 4-1BB expression on Treg cells compared with CD8 + effector cells, support development of human therapeutic anti-4-1BB isotype antibodies selected for their capacity to deplete Treg cells (Furness et al., 2014) . Our data support findings recently reported in Arce Vargas et al. (2017) , indicating that Treg celldepleting antibodies may synergize with checkpoint blockade to boost responses and help overcome resistance.
Our findings to this point support the contention that immunomodulatory mAbs can harness multiple mechanisms of action for therapy and we wanted to test the possibility that a single antibody could be engineered to carry out both depletion and agonism. Given our data demonstrating the competing FcgR requirements for these mechanisms in vitro and in vivo, it seemed unlikely that engineering a mAb to possess enhanced activatory and inhibitory FcgR engagement would work given that any one mAb can only engage a single FcgR at a time. Given these potential limitations, we generated a mIgG2a mAb with optimal depleting capacity to incorporate the hIgG2 hinge region which we skewed to the agonism-optimal B form. We hypothesized that this mAb would be able to perform both functions and found this to be the case both in vitro and in vivo; this mAb also led to enhanced therapy in a solid tumor model. These results have direct implications for the administration of existing and in-development immunomodulatory mAbs and potentially for the design and development of next-generation reagents and strategies for their use.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Mice were used in these studies as the least sentient species with an immune system comparable to humans. The availability of transgenic mouse strains also facilitates more detailed understanding of the therapeutic mechanisms used by mAbs to inform clinical translation. C57BL/6, BALB/c, A/J and Foxp3-GFP mice were maintained and bred in house. OT-1 TCR transgenic mice (C57BL/6 background) were purchased from Charles River and subsequently bred in house. Fcer1g . Expected mouse genotypes were confirmed by PCR and/or flow cytometry. All mice were bred in a closed research facility under specific pathogen-free conditions. PBMC-NOG/SCID mice (primary human xenograft model) were generated by injecting NOG mice with 15 3 10 6 PBMC isolated using
Ficoll-Paque PLUS in 200ul PBS. SCID mice were subsequently injected with 10 3 10 6 splenocytes from reconstituted NOG mice. Animal experiments were cleared through local ethical committee and were conducted under UK Home Office Project licenses PPL30/2964, PB24EEE31 and PA4C79999 and according to H.O. guidelines or at BioInvent under Dnr 14760/2016. Experiments used both male and female mice and mice were age and sex matched within experiments. For the majority of experiments mice were aged between 8-14 weeks. Littermates of the same sex were randomly assigned to experimental groups at the start of the experiment. In some experiments using CT26, mice were grouped after tumor injection but prior to treatment in order to equalise tumor size within groups. For the majority of experiments mice were maintained in SPF conditions in conventional open cages with immunocompromised strains maintained in individually ventilated cages. Food (irradiated RM1 (E)) and water was available ad libutum, mice were maintained on a 12 hour light/dark cycle and environmental enrichment was provided; temperature was maintained between 20-24 C. Mice were visually checked daily if adverse effects were anticipated or if mice were nearing a humane end-point.
Human subjects
For in vitro assays using human cells, PBMCs were obtained from anonymised leucocyte cones from the National Blood Service (Southampton UK) and used within 4 hours of preparation. Use of human blood samples was approved by local ethical committee. Human PBMCs used in experiments shown in Figure 
Cell lines
The CT26 colon carcinoma (Taraban et al., 2002) , NXS neuroblastoma (Lode et al., 1997) , B16/BL6 melanoma, B16-sFlt3L-Ig (FVAX: (Curran and Allison, 2009 )), EG7 (Moore et al., 1988) and Karpas-299 anaplastic large cell lymphoma stably transduced with a tail-less form of murine 4-1BB (pTL; (Buchan and Al-Shamkhani, 2012)) have all been described previously. Cells were maintained in a humidified incubator at 37 C and 5% CO 2 in Dulbecco's modified eagles medium (DMEM; EG7, B16/BL6 and FVAX) or RPMI-1640 (CT26, Karpas-299) supplemented with 10% heat inactivated FCS, 2mM L-glutamine, 1mM pyruvate, 100U/mL penicillin and 100mg/mL streptomycin. EG7 cells were additionally cultured in the presence of 0.4mg/mL geneticin which was removed one day prior to injection. NXS2 cells were maintained in DMEM supplemented with 10%FCS, 2mM L-glutamine and 0.1mM nonessential amino acids. All cells were cultured for a maximum of 3 months before returning to a frozen stock in order to prevent drift. Cell lines are routinely tested for mycoplasma in house. Prior to injection, cells were visualized under a microscope to ensure viability and verify that they exhibited the expected phenotype. The identity of Karpas-299 cells was verified previously by the surface expression of CD30 and expression of an ALK rearrangement (Buchan and Al-Shamkhani, 2012) . As expected melanoma cell lines appeared black in culture as a consequence of melanin expression.
METHOD DETAILS
Antibodies and reagents Anti-4-1BB (clone LOB12.0) mAb mIgG1, mIgG2a and mIgG2/huIgG2 CH1 hinge (mIgG2a/h2B) isotypes were constructed as previously described White et al., 2015) . Anti-CD8 (clone YTS169) was produced in house. Anti-mouse PD-1 (EW1-9) mAb rIgG1 was raised using conventional hybridoma technology after immunization of Wistar rats with recombinant mouse PD-1 (Leu25-Gln167) Fc fusion protein (R&D Systems). Spleen from immunized rats or mice were fused with NS-1 myeloma cells and plates screened by ELISA and flow cytometry. mAbs were initially screened and cells in positive wells were cloned twice and expanded in culture for IgG production. Antibodies were produced from hybridoma or CHOK1 cells and purified on Protein A with purity assessed by electrophoresis (Beckman EP system; Beckman Coulter, Buckinghamshire, UK) and lack of aggregation by SEC HPLC (all mAb less than 1%). All preparations were endotoxin low (< 10 EU endotoxin/mg) as determined using the Endosafe-PTS portable test system (Charles River Laboratories, L'Arbresle, FR). Anti-PD-1 de-gly was produced by treating EW1-9 with 0.05 U of PNGaseF/mg of antibody. N-Glycosidase F (PNGaseF) was obtained from Promega (V483A). Samples were kept at 37 C overnight. De-glycosylation was confirmed either by electrophoresis or SPR analysis. Purification of antibody from enzyme was achieved through size exclusion chromatography using sephadex TM 200. % Aggregation was less than 1% for all mAbs. Peptides were either produced in house (SIINFEKL) or obtained from Peptide Protein Research Ltd (SIINFEKL, FETFEAKI). Other reagents are detailed in the Key Resources Table. PE-labeled SIINFEKL peptide/H-2K b tetramer was manufactured in house (Protein Core Facility, University of Southampton).
Surface Plasmon Resonance
Analyses of anti-4-1BB mAb interactions with soluble FcgR were assayed using a Biacore T100 (GE Healthcare Life Sciences, Buckinghamshire, UK). Antibodies or BSA as a control were immobilized at 5000 resonance units [RU] ) to the flow cells of CM5 sensor chips (GE Healthcare Life Sciences, Buckinghamshire, UK) by standard amine coupling according to the manufacturer's instructions. Soluble FcgR (R&D Systems, Abingdon, UK) were injected through the flow cells at 1500, 375, 94, 23, 6, and 0 nM in HBS-EP+ running buffer (GE Healthcare Life Sciences, Buckinghamshire, UK) at a flow rate of 30 ml/min. Soluble Fc receptor was injected for 2 min, and dissociation was monitored for 5 min. Background binding to the control flow cell was subtracted automatically. Affinity constants were derived from the data by equilibrium binding analysis as indicated using Biacore Bioevaluation software (GE Healthcare Life Sciences, Buckinghamshire, UK). To determine the binding of anti-PD-1 mAbs to FcgRs, an anti-histidine mAb (GE Healthcare) was used to capture FcgRI, IIB, III or IV onto a CM5 chip before soluble mAbs were passed on top. To demonstrate that anti-PD-1 mAb blocks PD-L1 binding to PD-1, recombinant PD-1-his (R&D Systems) was similarly captured on a CM5 chip with an anti-histidine mAb before passing over PD-L1-Fc (R&D Systems) or anti-PD-1 mAbs as indicated.
In vitro binding assays Karpas-299 cells stably transduced with a tail-less form of murine 4-1BB (pTL) were incubated with the concentrations of anti-4-1BB mAb indicated at 4 C for 20 min prior to washing and staining with a PE-labeled anti-mouse or anti-rat secondary antibody (Jackson Immunoresearch). No staining was observed to Karpas-299 cells stably expressing an empty vector control (data not shown). For the competitive binding assay, 0.1 mg/mL parental rat anti-4-1BB mAb was mixed with graded concentrations of either mIgG1 or mIgG2a versions of anti-4-1BB as indicated prior to incubation with Karpas-299 pTL cells. Cells were washed and stained with an APC-conjugated and mouse-adsorbed donkey anti-rat secondary antibody; the secondary antibody did not bind to either mIgG1 or mIgG2a (data not shown). Flow cytometric analysis was performed using a BD FACS Canto II and FACS Diva software. ) BALB/c mice were challenged with 5 3 10 4 CT26 cells s.c. on day 0. When tumors were palpable mice received mAb or PBS control i.v. followed by 3 further injections i.p. every other day (200 mg final dose unless otherwise indicated). Where CD8+ T cells were depleted, 0.5 mg of anti-CD8 (YTS169) was administered i.p. on days À1, +1, and +4 as previously described (French et al., 1999) relative to administration of tumor. For rechallenge experiments mice surviving the initial tumor challenge and naive control mice were rechallenged after day 100 with 5x10 4 CT26 cells s.c. and monitored for tumor growth.
Immunotherapy protocols
EG7 -Groups of age and sex matched C57BL/6, Tnfrsf9 fl/fl , Tnfrsf9 Foxp3À/À or Fcer1g À/À C57BL/6 mice were challenged with 5x10 5 EG7 cells s.c. on day 0 prior to injection of 200 mg mAb, 200 mg isotype control mAb or PBS control as indicated on days 3, 5 and 7 i.p.
NXS2 -Groups of age and sex matched A/J mice were challenged with 2x10 6 NXS2 cells s.c. on day 0 and received antibody/peptide vaccine as specified in individual experiments. All antibodies were given i.p. in PBS. Tyrosine Hydroxylase (FETFEAKI) and control (SIINFEKL) peptides in PBS were emulsified in equal volumes of incomplete Freunds adjuvant (IFA) before injection i.d. B16/BL6 -Groups of age and sex matched C57BL/6 mice were challenged with 2.5 3 10 4 B16/BL6 cells intra-dermally on day 0.
On days 3, 6 and 9 mice received 1 3 10 6 irradiated FVAX cells i.d. on the opposite flank and either PBS, 100 mg anti-CTLA-4 (clone 9D9) or anti-CTLA-4 and 300 mg anti-4-1BB antibodies as indicated i.p. also on day 3, 6 and 9 based on our previously published protocol (Curran et al., 2011) . In all models, tumor growth was regularly monitored by caliper and mice culled when cross-sectional area exceeded 225 mm 2 .
In vitro cell proliferation Spleens from Foxp3-GFP mice were sorted on a FACsAria to exclude GFP+ cells (-Tregs; 99% of Treg cells removed; data not shown) or null sorted and plated at 1 3 10 5 cells/well with 0.1 mg/mL anti-CD3 (145.2C11) and a range of anti-4-1BB mAb concen-
